In MM, the efficacy of the third-generation BCMA- and CD19-CAR constructs (CD28-OX40-CD3ζ) were tested by infusing the product cocktail into RRMM patients, post-ASCT. The gene discussed is CD19; the disease is Miyoshi myopathy.